Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
Earnings Data
Report Date
Feb 04, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.64Last Year’s EPS
0.58Same Quarter Last Year
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted GSK's strong financial performance, significant growth in specialty medicines, and progress in R&D with FDA approvals. However, challenges remain in the U.S. vaccine market, delays in the HIV treatment study, and impacts from Medicare redesign and Zantac settlements.Company Guidance
Strong Financial Performance
Total sales were up 8% for the quarter, with core operating profit up 11% and core earnings per share up 14% to 55p. Cash generation continues to be very positive at GBP 6.3 billion for the year so far.
Specialty Medicines Growth
Specialty Medicines saw a 16% increase with strong growth in RI&I, oncology, and HIV. Benlysta and Nucala grew by 17% and 14%, respectively. Jemperli sales increased for the 10th consecutive quarter.
R&D Progress and FDA Approvals
GSK secured four FDA approvals this year, including BLENREP, with a fifth, depemokimab, expected before year-end. GSK continues to strengthen its late-stage portfolio and plans significant investment in R&D.
Upgraded Guidance
GSK upgraded its guidance for the year with meaningful improvement for 2025 sales and profits. Sales expectations increased from 3%-5% to 6%-7%, operating profit to 9%-11%, and EPS to 10%-12%.
Vaccine Sales Growth
Shingrix sales grew 13% overall, with a strong performance in Europe (up 48%). Arexvy and Bexsero also showed strong demand.
GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 29, 2025 | $43.70 | $45.93 | +5.10% |
Jul 30, 2025 | $37.27 | $38.55 | +3.43% |
Apr 30, 2025 | $38.11 | $38.97 | +2.26% |
Feb 05, 2025 | $33.70 | $36.47 | +8.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GlaxoSmithKline (GSK) report earnings?
GlaxoSmithKline (GSK) is schdueled to report earning on Feb 04, 2026, Before Open (Confirmed).
What is GlaxoSmithKline (GSK) earnings time?
GlaxoSmithKline (GSK) earnings time is at Feb 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GSK EPS forecast?
GSK EPS forecast for the fiscal quarter 2025 (Q4) is 0.64.
